• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Announces Second Partner VLN Product Deal as Part of Major Pinnacle Brand Expansion Agreement with Top-5 C-Store Chain

    6/24/25 9:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    Launching New Pinnacle VLN and Moist Snuff Products in More Than 1,700 Stores Across 27 States 

    MOCKSVILLE, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category. The agreement includes a merchandising agreement to potentially expand the availability of Pinnacle products to include other retail and c-store chains.

    "We are very excited to launch our second partner VLN® product and branded moist snuff products, leveraging the well-known Pinnacle brand sold at one of the largest convenience store chains in the U.S.," stated Larry Firestone, 22nd Century Group Chief Executive Officer. "Pinnacle's conventional cigarette and cigarillo products have built a strong sales track record with consumers, owing to extensive marketing and awareness directed by the chain and a compelling value proposition for adult smokers. We believe Pinnacle branded products in the VLN® and moist snuff categories can see similar success with customers at this c-store chain's more than 1,700 stores."

    The new agreement includes two partner VLN products, Pinnacle VLN® Gold cigarettes and Pinnacle Menthol VLN® cigarettes which will be sold at approximately 1,700 stores across 27 states. Sales to customers are expected to begin in late summer and early fall of 2025, with stocking orders in advance, as state approvals are secured.



    Additionally, two SKUs of Pinnacle moist snuff products, straight and wintergreen flavors, are expected to begin sales across the c-store's network in the second half of 2025 as state regulatory approvals are secured.



    22nd Century Group provides the trademarked Pinnacle brand name, manufacturing services and predicate tobacco blend for Pinnacle's conventional products that were launched in 2023, as well as distribution to the retail stores and state tax stamp compliance through its national-scale distribution agreements. Similarly, the new partner branded Pinnacle VLN® cigarettes will be produced at 22nd Century's manufacturing operations in North Carolina using proprietary VLN® tobacco strains and distributed across the chain through these distribution channels. Pinnacle cigarillo products are produced using a third-party model and distributed by 22nd Century, with Pinnacle moist snuff products expected to use a similar approach.

    About 22nd Century Group, Inc.

    22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption. 

    We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to allow consumers to greatly reduce their nicotine consumption. Instead of offering new ways of delivering nicotine to smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.

    Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combustible tobacco products annually with additional space for expansion. 

    Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.

    VLN® is a registered trademark of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 20, 2025, and in the Company's Quarterly Report filed on May 13, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Investor Relations & Media Contact

    Matt Kreps

    Investor Relations

    22nd Century Group

    [email protected]

    214-597-8200



    Primary Logo

    Get the next $XXII alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arno Andrew was granted 17,295 shares, increasing direct ownership by 9,298% to 17,481 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/14/25 4:58:49 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP of Sales and Marketing Manfredonia Robert P was granted 32,429 shares, increasing direct ownership by 5,123% to 33,062 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:40:01 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    VP and Deputy General Counsel Staffeldt Jonathan was granted 37,146 shares, increasing direct ownership by 5,124% to 37,871 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    11/13/25 5:38:22 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    SEC Form S-3 filed by 22nd Century Group Inc.

    S-3 - 22nd Century Group, Inc. (0001347858) (Filer)

    3/31/26 5:00:54 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by 22nd Century Group Inc.

    S-8 - 22nd Century Group, Inc. (0001347858) (Filer)

    3/27/26 4:30:40 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 8-K filed by 22nd Century Group Inc.

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    3/26/26 8:02:51 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group to Announce Fourth Quarter and Full Year 2025 Results on March 26, 2026

    MOCKSVILLE, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, will host a webcast on Thursday, March 26, 2026, at 8:00 AM ET to discuss its 2025 fourth quarter and full year results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the recent months and update plans for the 2026 year. The live and archived webcast will

    3/23/26 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Continued Early Sales Momentum for VLN® Cigarette Products

    Expansion in 2026 Forecasted to Exceed 5,000 Retail Outlets Nationwide as Consumers Demonstrate Interest in VLN® Brands VLN® Remains the Only FDA-Authorized Combustible Cigarette Designed to Reduce Nicotine Consumption MOCKSVILLE, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced continued early sales momentum for its VLN® low nicotine cigarette products in the U.S. market. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reducing nicotine consumption. 22n

    2/23/26 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care